High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin

BMC Cancer

Frank Tacke⁵  Oliver Galm³  Nicolas Kanig²  Eray Yagmur¹  Sabine Brandt²  Jonathan A Lindquist²  Christiane S Eberhardt²  Ute Raffetseder⁴  Peter R Mertens² 

[1] Medical Care Center, Dr. Stein and colleagues, 41061 Mönchengladbach, Germany

[2] Department of Nephrology and Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany

[3] Medical Clinic IV, University Hospital RWTH-Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany

[4] Medical Clinic II, University Hospital RWTH-Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany

[5] Medical Clinic III, University Hospital RWTH-Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany

关键词: YB-1;    Prognosis;    Cancer screening;    Serum biomarker;    Cancer disease;    Cold shock proteins;   

Others  :  859123
DOI  :  10.1186/1471-2407-14-33

 received in 2013-03-25, accepted in 2013-10-31,  发布年份 2014

【 摘 要 】

Background

Expression of the cold shock protein Y-box protein 1 (YB-1) is associated with deleterious outcome in various malignant diseases. Our group recently showed that the detection of an 18 kDa YB-1 fragment (YB-1/p18) in human plasma identifies patients with malignant diseases. We now tested the prevalence, clinical, and diagnostic value of YB-1/p18 detection in common tumors.

Methods

A newly established monoclonal YB-1 antibody was used to detect YB-1/p18 by immunoblotting in plasma samples from 151 unselected tumor patients, alongside established tumor markers and various diagnostic measures, during evaluation for a cancerous disease and in follow-up studies after therapeutic interventions.

Results

Circulating YB-1/p18 was detected in 78% of patients having a tumor disease. YB-1/p18 positivity was highly prevalent in all examined malignancies, including lung cancer (32/37; 87%), breast cancer (7/10; 70%), cancer of unknown primary (CUP; 5/5, 100%) or hematological malignancies (42/62; 68%). Positivity for YB-1/p18 was independent of other routine laboratory parameters, tumor stage, or histology. In comparison to 13 established tumor markers (cancer antigens 15–3, 19–9, 72–4, and 125; carcinoembryonic antigen; cytokeratin fragments 21–1; neuron-specific enolase; alpha-fetoprotein; beta-2-microglobulin; squamous cell carcinoma antigen; thymidine kinase; tissue polypeptide antigen; pro-gastrin-releasing peptide), YB-1/p18 detection within serum samples was the most sensitive general parameter identifying malignant disorders. YB-1/p18 concentrations altered during therapeutic interventions, but did not predict prognosis.

Conclusions

Plasma YB-1/p18 detection has a high specific prevalence in malignancies, thereby providing a novel tool for cancer screening independent of the tumor origin.

【 授权许可】

   
2014 Tacke et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Brandt S, Raffetseder U, Djudjaj S, Schreiter A, Kadereit B, Michele M, Pabst M, Zhu C, Mertens PR: Cold shock Y-box protein-1 participates in signaling circuits with auto-regulatory activities. Eur J Cell Biol 2011, 91(6–7):464-471.
• [2]Lasham A, Print CG, Woolley AG, Dunn SE, Braithwaite AW: YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J 2013, 449(1):11-23.
• [3]Raffetseder U, Frye B, Rauen T, Jurchott K, Royer HD, Jansen PL, Mertens PR: Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. J Biol Chem 2003, 278(20):18241-18248.
• [4]Bommert KS, Effenberger M, Leich E, Kuspert M, Murphy D, Langer C, Moll R, Janz S, Mottok A, Weissbach S, et al.: The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia 2012, 27(2):441-450.
• [5]Sinnberg T, Sauer B, Holm P, Spangler B, Kuphal S, Bosserhoff A, Schittek B: MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp Dermatol 2012, 21(4):265-270.
• [6]Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, et al.: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997, 3(4):447-450.
• [7]Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, et al.: YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005, 65(10):4078-4087.
• [8]Hyogotani A, Ito K, Yoshida K, Izumi H, Kohno K, Amano J: Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer. Clin Lung Cancer 2012, 13(5):375-384.
• [9]Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M: Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001, 7(10):3151-3155.
• [10]Yoshimatsu T, Uramoto H, Oyama T, Yashima Y, Gu C, Morita M, Sugio K, Kohno K, Yasumoto K: Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. Anticancer Res 2005, 25(5):3437-3443.
• [11]Frye BC, Halfter S, Djudjaj S, Muehlenberg P, Weber S, Raffetseder U, En-Nia A, Knott H, Baron JM, Dooley S, et al.: Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO reports 2009, 10(7):783-789.
• [12]Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, Trautwein C, Mertens PR: Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer 2011, 11:185. BioMed Central Full Text
• [13]Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, et al.: Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer 2009, 9:410. BioMed Central Full Text
• [14]Yagmur E, Trautwein C, Gressner AM, Tacke F: Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006, 101(6):1244-1252.
• [15]Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Critical care 2011, 15(1):R63. BioMed Central Full Text
• [16]Rizki A, Weaver VM, Lee SY, Rozenberg GI, Chin K, Myers CA, Bascom JL, Mott JD, Semeiks JR, Grate LR, et al.: A human breast cell model of preinvasive to invasive transition. Cancer Res 2008, 68(5):1378-1387.
• [17]Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002, 97(3):278-282.
• [18]Mo MH, Chen L, Fu Y, Wang W, Fu SW: Cell-free circulating miRNA biomarkers in cancer. J Cancer 2012, 3:432-448.
• [19]Roderburg C, Mollnow T, Bongaerts B, Elfimova N, Vargas Cardenas D, Berger K, Zimmermann H, Koch A, Vucur M, Luedde M, et al.: Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PloS one 2012, 7(3):e32999.
• [20]Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M, Tsuneyoshi M: Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003, 199(2):251-258.
• [21]Schmalfuss F, Kolominsky-Rabas PL: Personalized medicine in screening for malignant disease: a review of methods and applications. Biomarker Insights 2013, 8:9-14.